EyeGene (185490) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, EyeGene (185490) reported revenue of 3.6 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
20253.6 billion KRW-9.9 billion KRW-19.1 billion KRW[source]
20243.4 billion KRW-13.3 billion KRW-12.9 billion KRW[source]
20233.1 billion KRW-27.1 billion KRW-22.4 billion KRW[source]
20225.3 billion KRW-24.1 billion KRW-26.5 billion KRW[source]
20213.2 billion KRW-35.0 billion KRW-34.6 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
202566.3 billion KRW8.0 billion KRW58.3 billion KRW[source]
202458.6 billion KRW9.3 billion KRW49.3 billion KRW[source]
202372.6 billion KRW10.2 billion KRW62.4 billion KRW[source]
202277.4 billion KRW11.2 billion KRW66.2 billion KRW[source]
2021104.4 billion KRW16.0 billion KRW88.4 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice